Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.262
Index Copernicus (ICV) – 155.19, MNiSW – 15
Average rejection rate – 84.38%
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 8, August, p. 1045–1054

doi: 10.17219/acem/69247

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Performance evaluation of HBsAg by Lumipulse HBsAg-HQ: The agreement with HBsAg by Architect HBsAg-QT and the effectiveness in predicting liver tissue pathological states of chronic hepatitis B patients

Zhanqing Zhang1,A,C,D,F, Rongrong Ding1,B,D, Wei Lu1,B,E, Zhiqiang Yang2,E, Yanbing Wang1,B, Xinlan Zhou1,B, Dan Huang1,B, Xiufen Li1,B, Yanling Feng1,B

1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

2 Fujirebio Shanghai Representative Office, Shanghai, China

Abstract

Background. A novel high-sensitivity HBsAg quantification assay, Lumipulse HBsAg-HQ, was developed. However, its performance in practical application has not yet been adequately investigated.
Objectives. The aim of the study was to evaluate the agreement of serum HBsAg by Lumipulse HBsAg-HQ (HBsAg-HQ) with HBsAg by Architect HBsAg-QT (HBsAg-QT) and comparatively investigate the efficacy of serum HBsAg-HQ and HBsAg-QT in predicting the liver tissue pathological states of chronic hepatitis B (CHB) patients.
Material and Methods. A total of 147 HBeAg-positive and 128 HBeAg-negative patients were enrolled. HBsAg-HQ and HBsAg-QT were measured using CLEIA Lumipulse G1200 and CMIA Abbott Architect I2000 automatic analyzer, respectively. The Scheuer standard was used for the pathological diagnosis of liver tissue samples.
Results. In both HBeAg-positive and HBeAg-negative patients, HBsAg-HQ was significantly positively correlated with HBsAg-QT (r = 0.913 and r = 0.959, respectively), the overall disagreement rates between HBsAg-HQ and HBsAg-QT were 2.72% (4/147) and 4.69% (6/128), respectively. In HBeAg-positive patients, the area under the ROC curve (AUC) of HBsAg-HQ and HBsAg-QT for predicting the grade ≥G3 (0.686 and 0.684, respectively) and stage ≥S4 (0.739 and 0.745, respectively) were the greatest compared with other pathological states; the optimal cutoffs of HBsAg-HQ and HBsAg-QT for predicting the grade ≥G3 were <2.244 × 107 mIU/mL and <3.589 × 107 mIU/mL, and those for predicting the stage ≥S4 were 7.328 × 106 mIU/mL and <6.194 × 106 mIU/mL, respectively.
Conclusion. HBsAg-HQ is highly correlated and in agreement with HBsAg-QT in both HBeAg-positive and HBeAg-negative patients; HBsAg-HQ and HBsAg-QT are very valuable in predicting the grade ≥G3 and stage ≥S4 in HBeAg-positive patients.

Key words

hepatitis B surface antigen, performance evaluation, Lumipulse HBsAg-HQ, pathology, noninvasive diagnosis

References (29)

  1. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004;115:217–222. doi:10.1016/j.jviromet.2003.10.002
  2. Wong GLH, Chan HLY. Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. Clin Liver Dis. 2013;2:8–10. doi:10.1002/cld.165
  3. Zhou B, Liu M, Lv G, et al. Quantification of hepatitis B surface antigen and e antigen: Correlation between Elecsys and Architect assays. J Viral Hepat. 2013;20:422–429. doi:10.1111/jvh.12044
  4. Park Y, Hong DJ, Shin S, et al. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: Two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay. Am J Clin Pathol. 2012;137:770–777. doi:10.1309/AJCP8QDN7NAUXJFJ
  5. Tan Z, Li M, Kuang X, et al. Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection. J Clin Virol. 2014;59:228–234. doi:10.1016/j.jcv.2014.01.013
  6. Wang L, Zou ZQ, Wang K, et al. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int. 2016;10:133–138. doi:10.1007/s12072-015-9657-6
  7. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol. 2013;58: 1089–1095. doi:10.1016/j.jhep.2013.01.028
  8. Goyal SK, Jain AK, Dixit VK, et al. HBsAg level as predictor of liver fibrosis in HBeAg positive patients with chronic hepatitis B virus infection. J Clin Exp Hepatol. 2015;5:213–220. doi:10.1016/j.jceh.2015.04.008
  9. Moucari R, Marcellin P. Quantification of hepatitis B surface antigen: A new concept for the management of chronic hepatitis B. Liver Int. 2011;31(Suppl 1):122–128. doi:10.1111/j.1478-3231.2010.02390.x
  10. Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441–450. doi:10.1002/hep.26041
  11. Matsubara N, Kusano O, Sugamata Y, et al. A novel hepatitis B virus surface antigen immunoassay as sensitive ashepatitis B virus nucleic acid testing in detecting early infection. Transfusion. 2009;49:585–595. doi:10.1111/j.1537-2995.2008.02026.x
  12. Seto WK, Tanaka Y, Wong DK, et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int. 2013;7:98–105. doi:10.1007/s12072-012-9354-7
  13. Seto WK, Tanaka Y, Wong DK, et al. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: Re-evaluation of HBsAg seroclearance. Liver Int. 2016;36:642–650. doi:10.1111/liv.12980
  14. Shinkai N, Matsuura K, Sugauchi F, et al. Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. J Clin Microbiol. 2013;51:3484–3491. doi:10.1128/JCM.00726-13
  15. Duong LT, Coignard C. Evaluation of a new high sensitive, qualitative and quantitative Hepatitis B surface antigen assay. J Clin Virol. 2015;70(Suppl 1):S95.
  16. Choi SJ, Park Y, Lee EY, et al. Performance evaluation of Lumipulse G1200 autoimmunoanalyzer for the detection of serum hepatitis B virus markers. J Clin Lab Anal. 2013;27:204–206. doi:10.1002/jcla.21584
  17. Yang R, Song G, Guan W, et al. The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. J Virol Methods. 2016;228:39–47. doi:10.1016/j.jviromet.2015.11.016
  18. Seto WK, Wong DK, Fung J, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20:1173–1180. doi:10.1111/1469-0691.12739
  19. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 2016;10:1–98. doi:10.1007/s12072-015-9675-4
  20. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology. 2000;31:241–246. doi:10.1002/hep.510310136
  21. Cheng XD, Song LW, Fang LL, et al. Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. Clin Vaccine Immunol. 2014;21:1521–1527. doi:10.1128/CVI.00529-14
  22. Suh SJ, Bae SI, Kim JH, et al. Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection. J Med Virol. 2014;86:117–123. doi:10.1002/jmv.23767
  23. Zeng LY, Lian JS, Chen JY, et al. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: A Chinese perspective study. World J Gastroenterol. 2014;20:9178–9184. doi:10.3748/wjg.v20.i27.9178
  24. Cheng PN, Tsai HW, Chiu YC, et al. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol. 2013;57:323–330. doi:10.1016/j.jcv.2013.04.012
  25. Jia W, Qi X, Ji YY, et al. Low serum hepatitis B surface antigen level predicts compensated cirrhosis caused by chronic hepatitis B in HBeAg positive patients in east China. Hepat Mon. 2015;15:e29183. doi: 10.5812/hepatmon.29183
  26. Xun YH, Zang GQ, Guo JC, et al. Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. J Gastroenterol Hepatol. 2013;28:1746–1755. doi:10.1111/jgh.12304
  27. Seto WK, Wong DK, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7:e43087. doi:10.1371/journal.pone.0043087
  28. Alam S, Ahmad N, Mustafa G, et al. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B. Liver Int. 2011;31:824–830. doi:10.1111/j.1478-3231.2011.02491.x
  29. Croagh CMN, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30:1115–1122. doi:10.1111/j.1478-3231.2010.02267.x